Nirvana Life Sciences Inc. NIRVX
CNSX
| 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.50K | 57.60K | 33.40K | 120.10K | 44.00K |
| Depreciation & Amortization | -- | -- | -- | -8.60K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.50K | 57.60K | 33.40K | 111.50K | 44.00K |
| Operating Income | -34.50K | -57.60K | -33.40K | -111.50K | -44.00K |
| Income Before Tax | -38.60K | -65.50K | -26.50K | -119.20K | -55.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.60K | -65.50K | -26.50K | -119.20K | -55.60K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 200.00 | -- | 0.00 | -500.00 | 200.00 |
| Net Income | -38.40K | -65.50K | -26.50K | -119.60K | -55.40K |
| EBIT | -34.50K | -57.60K | -33.40K | -111.50K | -44.00K |
| EBITDA | -- | -- | -- | -108.20K | -40.80K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 |
| Average Basic Shares Outstanding | 22.82M | 22.93M | 22.82M | 4.82M | 48.23M |
| Average Diluted Shares Outstanding | 22.82M | 22.93M | 22.82M | 4.82M | 48.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |